{"id":"azilsartan-medoxomil-and-hydrochlorothiazide","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hyperkalemia (elevated potassium)"},{"rate":null,"effect":"Hypokalemia (low potassium)"},{"rate":null,"effect":"Hyperuricemia (elevated uric acid)"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Azilsartan medoxomil is an angiotensin II receptor blocker (ARB) that selectively antagonizes AT1 receptors, preventing vasoconstriction and aldosterone release. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing blood volume and electrolyte levels. The combination provides complementary antihypertensive effects through different mechanisms.","oneSentence":"Azilsartan medoxomil blocks angiotensin II receptors to lower blood pressure, while hydrochlorothiazide is a thiazide diuretic that reduces fluid volume.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:03:21.360Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension (high blood pressure)"}]},"trialDetails":[{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT03006796","phase":"","title":"Observational Study of Azilsartan/Chlorthalidone and Irbesartan/Hydrochlorothiazide in Hypertension and Obesity.","status":"COMPLETED","sponsor":"Russian Heart Failure Society","startDate":"2017-01-16","conditions":"Arterial Hypertension","enrollment":94},{"nctId":"NCT02072330","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.","status":"COMPLETED","sponsor":"Takeda","startDate":"2013-03","conditions":"Grade I or II Essential Hypertension","enrollment":353},{"nctId":"NCT01309828","phase":"PHASE3","title":"Long-Term Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Hypertension and Kidney Disease","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-03","conditions":"Safety","enrollment":153},{"nctId":"NCT00996281","phase":"PHASE3","title":"Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-10","conditions":"Essential Hypertension","enrollment":837},{"nctId":"NCT00846365","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-03","conditions":"Essential Hypertension","enrollment":1085},{"nctId":"NCT00818883","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-02","conditions":"Essential Hypertension","enrollment":609},{"nctId":"NCT01033071","phase":"PHASE3","title":"Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.","status":"COMPLETED","sponsor":"Takeda","startDate":"2010-01","conditions":"Essential Hypertension","enrollment":1071},{"nctId":"NCT00695955","phase":"PHASE3","title":"One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-06","conditions":"Hypertension","enrollment":669}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["TAK-491","TAK-491CLD"],"phase":"phase_3","status":"active","brandName":"Azilsartan medoxomil and hydrochlorothiazide","genericName":"Azilsartan medoxomil and hydrochlorothiazide","companyName":"Takeda","companyId":"takeda","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Azilsartan medoxomil blocks angiotensin II receptors to lower blood pressure, while hydrochlorothiazide is a thiazide diuretic that reduces fluid volume. Used for Hypertension (high blood pressure).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}